Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Clinical trial NCT05302024 · UNKNOWN
Trial details
- NCT number
- NCT05302024
- Sponsor
- Peking University People's Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-22
- Primary completion
- 2023-12-12
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.